Evaluating the potential of the GFAP-KLH immune-tolerizing vaccine for type 1 diabetes in mice

Autor: Shota Yoshida, Masayoshi Higuchi, Hiromi Rakugi, Ryuichi Morishita, Munehisa Shimamura, Hitomi Kurinami, Hiroshi Koriyama, Yoichi Takami, Zhengda Pang, Hironori Nakagami
Rok vydání: 2016
Předmět:
0301 basic medicine
endocrine system diseases
Biophysics
macromolecular substances
Biochemistry
03 medical and health sciences
chemistry.chemical_compound
Interferon-gamma
0302 clinical medicine
Immune system
Th2 Cells
Structural Biology
Mice
Inbred NOD
Glial Fibrillary Acidic Protein
Genetics
medicine
Immune Tolerance
Cytotoxic T cell
Animals
Secretion
Molecular Biology
Pancreas
Type 1 diabetes
Vaccines
Glial fibrillary acidic protein
biology
C-Peptide
C-peptide
Pancreatic islets
Vaccination
Immunity
nutritional and metabolic diseases
Cell Biology
Th1 Cells
medicine.disease
030104 developmental biology
medicine.anatomical_structure
Diabetes Mellitus
Type 1
Phenotype
nervous system
chemistry
Immunoglobulin G
Immunology
Hemocyanins
biology.protein
Female
Interleukin-4
030217 neurology & neurosurgery
Zdroj: FEBS letters. 591(1)
ISSN: 1873-3468
Popis: Glial fibrillary acidic protein (GFAP), expressed in peri-islet Schwann cells, is a novel target for the treatment of type 1 diabetes mellitus (T1DM). We designed a GFAP immune-tolerizing vaccine that successfully suppresses hyperglycemia and enhances C peptide secretion. The GFAP vaccine significantly prevented T cell infiltration into pancreatic islets. Moreover, after GFAP vaccination, naive T-cell differentiation shifted from a cytotoxic Th1- to a Th2-biased humoral response. These results indicate that as a novel target, GFAP reliably predicts the development of T1DM, and that the GFAP vaccine successfully delays the progression of T1DM by regulating T-cell differentiation.
Databáze: OpenAIRE
Externí odkaz: